

Aus dem Institut für Experimentelle Neurologie  
der Medizinischen Fakultät Charité – Universitätsmedizin Berlin

DISSERTATION

A possible role of the Na<sup>+</sup>/K<sup>+</sup>-ATPase in the pathomechanism  
of spreading ischemia.

zur Erlangung des akademischen Grades  
Doctor medicinae (Dr. med.)

vorgelegt der Medizinischen Fakultät  
Charité – Universitätsmedizin Berlin

von

Stoigniew Sebastian Major

aus Bendzin/Polen

Datum der Promotion: 10.03.2017

## Table of contents

|  |    |
|--|----|
| Abstract.....  | 1  |
| Abstract (German).....   | 2  |
| Affidavit .....  | 3  |
| Excerpt of the Journal Summary List (ISI Web of Knowledge <sup>SM</sup> )..... | 4  |
| “A role of the sodium pump in spreading ischemia in rats” .....                | 6  |
| Supplemental material.....   | 25 |
| Curriculum vitae.....  | 34 |
| List of publications .....   | 35 |
| Acknowledgements .....   | 38 |

## Abstract

Spreading depolarization (SD) is characterized by a sustained neuronal depolarization and near-complete breakdown of the ion gradients across the cellular membranes. The recovery from SD is energy-dependent. Accordingly the local parenchymal ATP concentration falls by 45%. In healthy tissue the increased energy demand is satisfied by a marked rise in cerebral blood flow (CBF), but this hemodynamic response can become inverted under pathologic conditions like subarachnoid hemorrhage, cerebral ischemia or traumatic brain injury. Under this condition SD induces long-lasting vasoconstriction, which spreads together with the depolarization wave in the tissue. In an experimental animal model the resulting spreading ischemia (SI) led to cortical infarcts. SI occurs when SD runs in tissue with increased baseline extracellular potassium ( $[K^+]_o$ ) and depletion of nitric oxide (NO).

In cell culture chronically increased  $[K^+]_o$  reduces the activity of the sodium-potassium ATPase (NaKA). Therefore, we tested *in vivo* if direct inhibition of NaKA with ouabain induces SI in rats when the NO concentration is simultaneously decreased.

First we confirmed that chronically increased  $[K^+]_o$  also reduces NaKA activity *in vivo*. Notably the  $\alpha_2/\alpha_3$  isoforms were selectively affected. We then found that ouabain, in a concentration selectively inhibiting the  $\alpha_2/\alpha_3$  isoforms, induced SI when NO was simultaneously depleted.

What could be the mechanism underlying this effect of  $\alpha_2/\alpha_3$  NaKA inhibition? The  $\alpha_2/\alpha_3$  isoforms are colocalized with the  $Na^+/Ca^{2+}$ -exchanger (NCX) at cell membrane sites adjacent to the (sarco-)endoplasmic reticulum (SER). Inhibition of the  $\alpha_2/\alpha_3$  isoforms decreases the local sodium gradient across the cell membrane, which consequently reduces the amount of  $Ca^{2+}$  transported out of the cell by the NCX. The surplus  $Ca^{2+}$  is then stored in the SER and might directly increase calcium dependent contractility of vascular smooth muscle cells and pericytes. Their contractility is additionally enhanced by increased  $Ca^{2+}$  release from astrocytic SER and consequent release of vasoconstrictive substances from astrocytes. These processes appear to play a specific role for the duration of SI because thapsigargin, depleting  $Ca^{2+}$  from the SER, significantly shortened SI.

These results are clinically relevant because we and others showed that SD and SI occur in patients with the above-mentioned diseases and are associated with unfavorable outcome. Better understanding of the pathomechanisms underlying SI may lead to the development of new diagnostic and therapeutic strategies for clinical conditions associated with SD and SI.

## Abstract (German)

Spreading Depolarization (SD) zeichnet sich durch einen fast vollständigen Zusammenbruch des neuronalen Membranpotentials aus, der durch massive Ionenverschiebungen zwischen Intra- und Extrazellulärraum verursacht wird. Die Wiederherstellung der physiologischen Ionenkonzentrationen führt bereits nach einer einzigen SD zur Reduktion der ATP-Konzentration im betroffenen Hirngewebe auf etwa 55% des Ausgangsniveaus. Dieser erhöhte Energiebedarf wird im gesunden Hirngewebe durch einen Blutflussanstieg ausgeglichen.

Unter pathologischen Umständen, z.B. nach einer Subarachnoidalblutung, einem Hirninfarkt, oder -trauma, kann es zur Umkehr dieser Blutflussantwort kommen. Dann induziert SD eine anhaltende Vasokonstriktion, die zu einer wandernden Mangeldurchblutung führt (englisch = Spreading Ischemia (SI)) und im Tiermodell kortikale Infarkte verursacht. Experimentell wird SI beobachtet, wenn die extrazelluläre Basis- $K^+$ -Konzentration ( $[K^+]_o$ ) vor der SD erhöht und gleichzeitig die NO-Konzentration ( $[NO]$ ) erniedrigt ist.

In der Zellkultur reduziert chronische Erhöhung der  $[K^+]_o$  die Aktivität der Natrium-Kalium-ATPase (NaKA). Daher haben wir in der vorliegenden Arbeit untersucht, ob eine direkte Hemmung der NaKA mit Ouabain in Kombination mit  $[NO]$ -Erniedrigung bei Ratten zu SI führt.

Zunächst konnten wir auch *in-vivo* bestätigen, dass chronisch erhöhte  $[K^+]_o$  die Aktivität der NaKA reduziert, und zwar vorrangig die der  $\alpha_2/\alpha_3$  Isoformen. Dass dieser Mechanismus zur SI beitragen könnte, belegten wir dadurch, dass wir SI auch durch direkte Inhibition der  $\alpha_2/\alpha_3$  Isoformen mit Ouabain bei gleichzeitiger  $[NO]$ -Verminderung induzieren konnten.

Auf welche Weise führt eine Hemmung der  $\alpha_2/\alpha_3$  NaKA zu verstärkter SD-induzierter Vasokonstriktion während SI? Die  $\alpha_2/\alpha_3$  Isoformen der NaKA werden gemeinsam mit dem  $Na^+/Ca^{2+}$ -Austauscher (NCX) in Bereichen der Plasmamembran exprimiert, die in unmittelbarer Nachbarschaft zum (sarco-)endoplasmatischen Reticulum (SER) liegen. Inhibition der  $\alpha_2/\alpha_3$  Isoformen führt zum Abfall des lokalen  $Na^+$ -Gradienten über die Zellmembran. Dadurch kann der NCX weniger  $Ca^{2+}$  aus der Zelle heraustransportieren, welches stattdessen vermehrt in das SER gepumpt wird. Daraus resultiert eine direkt verstärkte  $Ca^{2+}$ -abhängige Kontraktilität von glatten Gefäßmuskelzellen und Perizyten. Außerdem nimmt ihre Kontraktilität auch indirekt als Folge verstärkter  $Ca^{2+}$ -Ausschüttung aus dem astrozytären SER mit nachfolgender Freisetzung vasokonstriktiver Substanzen aus Astrozyten zu. Diese Prozesse scheinen in besonderer Weise eine Rolle für die Dauer der SI zu spielen. So konnten wir SI deutlich verkürzen, indem wir mit Thapsigargin die  $Ca^{2+}$ -Konzentration im SER vor der SI-Induktion reduziert haben.

Die Ergebnisse dieser Arbeit sind klinisch relevant, da wir und andere zeigen konnten, dass SD und SI bei den oben erwähnten neurologischen Krankheitsbildern im Patienten auftreten und mit schlechterem Outcome assoziiert sind. Die Entschlüsselung der zugrundeliegenden Pathomechanismen kann zum besseren Verständnis dieser Krankheiten und zur Entwicklung neuer diagnostischer und therapeutischer Strategien beitragen.

## Affidavit

I, Stoigniew Sebastian Major certify under penalty of perjury by my own signature that I have submitted the thesis on the topic “A possible role of the Na<sup>+</sup>/K<sup>+</sup>-ATPase in the pathomechanism of spreading ischemia”. I wrote this thesis independently and without assistance from third parties, I used no other aids than the listed sources and resources.

All points based literally or in spirit on publications or presentations of other authors are, as such, in proper citations (see "uniform requirements for manuscripts (URM)" the ICMJE [www.icmje.org](http://www.icmje.org)) indicated. The section on methodology (in particular practical work, laboratory requirements, statistical processing) and results (in particular images, graphics and tables) corresponds to the URM (s.o) and are answered by me. My contribution in the selected publication for this dissertation corresponds to those that are specified in the following joint declaration with the responsible person and supervisor.

The importance of this affidavit and the criminal consequences of a false affidavit (section 156,161 of the Criminal Code) are known to me and I understand the rights and responsibilities stated therein.

Date

\_\_\_\_\_  
Signature

### Detailed Declaration of Contribution

Sebastian Major had the following share in the following publication:

Publication: Sebastian Major, Gabor C. Petzold, Clemens Reiffurth, Olaf Windmüller, Marco Foddis, Ute Lindauer, Eun-Jeung Kang and Jens P Dreier, **A role of the sodium pump in spreading ischemia in rats**, Journal of Cerebral Blood Flow & Metabolism, 2016. <http://dx.doi.org/10.1177/0271678X16639059>.


Contribution in detail: Sebastian Major worked on design, performed and analyzed all experiments in groups 4-10, 12-15, 23 and 24 (all together 89 *in-vivo* experiments). Further, he analysed the experiments in groups 21 and 22, interpreted the data, wrote the initial version of the manuscript, prepared the manuscript for submission and took part in revising the study according to the reviewer's comments.

Signature, date and stamp of the supervising University teacher

\_\_\_\_\_

Signature of the doctoral candidate

\_\_\_\_\_



Journal Summary List

[Journal Title Changes](#)

Journals from: subject categories **NEUROSCIENCES** [VIEW CATEGORY SUMMARY LIST](#)

Sorted by:  [SORT AGAIN](#)

Journals 1 - 20 (of 252)

Navigation icons: [1|2|3|4|5|6|7|8|9|10]

Page 1 of 13

[MARK ALL](#) [UPDATE MARKED LIST](#)

Ranking is based on your journal and sort selections.

| Mark                     | Rank | Abbreviated Journal Title<br>(linked to journal information) | ISSN      | JCR Data <sup>i</sup> |               |                      |                 |          |                 | Eigenfactor® Metrics <sup>j</sup> |                          |
|--------------------------|------|--|-----------|-----------------------|---------------|----------------------|-----------------|----------|-----------------|-----------------------------------|--------------------------|
|                          |      |  |           | Total Cites           | Impact Factor | 5-Year Impact Factor | Immediacy Index | Articles | Cited Half-life | Eigenfactor® Score                | Article Influence® Score |
| <input type="checkbox"/> | 1    | <a href="#">NAT REV NEUROSCI</a>                             | 1471-003X | 32989                 | 31.427        | 38.997               | 3.712           | 59       | 7.4             | 0.08289                           | 16.894                   |
| <input type="checkbox"/> | 2    | <a href="#">TRENDS COGN SCI</a>                              | 1364-6613 | 20396                 | 21.965        | 22.500               | 3.150           | 60       | 8.3             | 0.04585                           | 9.498                    |
| <input type="checkbox"/> | 3    | <a href="#">BEHAV BRAIN SCI</a>                              | 0140-525X | 7562                  | 20.771        | 24.308               | 2.750           | 20       | >10.0           | 0.01103                           | 10.686                   |
| <input type="checkbox"/> | 4    | <a href="#">ANNU REV NEUROSCI</a>                            | 0147-006X | 13226                 | 19.320        | 25.920               | 1.320           | 25       | >10.0           | 0.02423                           | 13.624                   |
| <input type="checkbox"/> | 5    | <a href="#">NAT NEUROSCI</a>                                 | 1097-6256 | 50204                 | 16.095        | 17.154               | 4.276           | 221      | 7.7             | 0.15492                           | 8.821                    |
| <input type="checkbox"/> | 6    | <a href="#">NEURON</a>                                       | 0896-6273 | 77446                 | 15.054        | 16.839               | 3.221           | 399      | 8.2             | 0.22320                           | 8.682                    |
| <input type="checkbox"/> | 7    | <a href="#">MOL PSYCHIATR</a>                                | 1359-4184 | 14510                 | 14.496        | 13.834               | 3.152           | 151      | 5.4             | 0.04317                           | 5.007                    |
| <input type="checkbox"/> | 8    | <a href="#">TRENDS NEUROSCI</a>                              | 0166-2236 | 19082                 | 13.555        | 14.695               | 2.441           | 68       | >10.0           | 0.03363                           | 6.266                    |
| <input type="checkbox"/> | 9    | <a href="#">ACTA NEUROPATHOL</a>                             | 0001-6322 | 13098                 | 10.762        | 9.762                | 2.500           | 116      | 6.7             | 0.03329                           | 3.483                    |
| <input type="checkbox"/> | 10   | <a href="#">BIOL PSYCHIAT</a>                                | 0006-3223 | 40812                 | 10.255        | 10.359               | 2.667           | 210      | 7.7             | 0.07948                           | 3.553                    |
| <input type="checkbox"/> | 11   | <a href="#">PROG NEUROBIOL</a>                               | 0301-0082 | 11430                 | 9.992         | 10.487               | 2.839           | 62       | 9.4             | 0.02014                           | 3.553                    |
| <input type="checkbox"/> | 12   | <a href="#">ANN NEUROL</a>                                   | 0364-5134 | 32934                 | 9.977         | 10.792               | 1.970           | 167      | 9.9             | 0.06054                           | 4.176                    |
| <input type="checkbox"/> | 13   | <a href="#">J PINEAL RES</a>                                 | 0742-3098 | 6906                  | 9.600         | 7.227                | 1.862           | 87       | 5.9             | 0.00816                           | 1.120                    |
| <input type="checkbox"/> | 14   | <a href="#">BRAIN</a>  | 0006-8950 | 44379                 | 9.196         | 10.418               | 2.422           | 244      | 8.5             | 0.08489                           | 3.846                    |
| <input type="checkbox"/> | 15   | <a href="#">NEUROSCI BIOBEHAV R</a>                          | 0149-7634 | 16868                 | 8.802         | 10.528               | 1.657           | 198      | 6.4             | 0.04123                           | 3.596                    |
| <input type="checkbox"/> | 16   | <a href="#">CEREB CORTEX</a>                                 | 1047-3211 | 26191                 | 8.665         | 8.335                | 2.043           | 282      | 6.7             | 0.06927                           | 3.290                    |
| <input type="checkbox"/> | 17   | <a href="#">SLEEP MED REV</a>                                | 1087-0792 | 3919                  | 8.513         | 9.258                | 2.062           | 48       | 6.6             | 0.00959                           | 3.247                    |
| <input type="checkbox"/> | 18   | <a href="#">SOC COGN AFFECT NEUR</a>                         | 1749-5016 | 3937                  | 7.372         | 7.332                | 0.888           | 250      | 3.3             | 0.01563                           | 2.590                    |
| <input type="checkbox"/> | 19   | <a href="#">NEUROPSYCHOPHARMACOL</a>                         | 0893-133X | 22005                 | 7.048         | 8.168                | 1.582           | 292      | 6.4             | 0.05006                           | 2.643                    |
| <input type="checkbox"/> | 20   | <a href="#">FRONT NEUROENDOCRIN</a>                          | 0091-3022 | 3146                  | 7.037         | 9.656                | 2.556           | 36       | 5.9             | 0.00801                           | 3.212                    |

[MARK ALL](#) [UPDATE MARKED LIST](#)


Journals 1 - 20 (of 252)

Navigation icons: [1|2|3|4|5|6|7|8|9|10]

Page 1 of 13

[Acceptable Use Policy](#)

Copyright © 2016 Thomson Reuters.



Journal Summary List

[Journal Title Changes](#)

Journals from: **subject categories NEUROSCIENCES** [VIEW CATEGORY SUMMARY LIST](#)

Sorted by: **Impact Factor** [SORT AGAIN](#)

Journals 21 - 40 (of 252)



Page 2 of 13

[MARK ALL](#) [UPDATE MARKED LIST](#)

Ranking is based on your journal and sort selections.

| Mark                                | Rank | Abbreviated Journal Title<br><i>(linked to journal information)</i> | ISSN      | JCR Data <sup>i</sup> |               |                      |                 |          |                 | Eigenfactor® Metrics <sup>i</sup> |                          |
|-------------------------------------|------|---|-----------|-----------------------|---------------|----------------------|-----------------|----------|-----------------|-----------------------------------|--------------------------|
|                                     |      |   |           | Total Cites           | Impact Factor | 5-Year Impact Factor | Immediacy Index | Articles | Cited Half-life | Eigenfactor® Score                | Article Influence® Score |
| <input type="checkbox"/>            | 21   | <a href="#">NEUROSCIENTIST</a>                                      | 1073-8584 | 3821                  | 6.837         | 6.675                | 1.708           | 48       | 7.1             | 0.00882                           | 2.404                    |
| <input type="checkbox"/>            | 22   | <a href="#">CURR OPIN NEUROBIOL</a>                                 | 0959-4388 | 12732                 | 6.628         | 7.284                | 1.604           | 164      | 8.2             | 0.03380                           | 3.559                    |
| <input type="checkbox"/>            | 23   | <a href="#">MOL NEURODEGENER</a>                                    | 1750-1326 | 2058                  | 6.563         | 5.709                | 0.672           | 58       | 3.7             | 0.00873                           | 1.797                    |
| <input type="checkbox"/>            | 24   | <a href="#">NEUROIMAGE</a>  | 1053-8119 | 78028                 | 6.357         | 7.289                | 1.500           | 1033     | 6.5             | 0.17239                           | 2.257                    |
| <input type="checkbox"/>            | 25   | <a href="#">J NEUROSCI</a>  | 0270-6474 | 173265                | 6.344         | 7.348                | 1.188           | 1486     | 8.0             | 0.38326                           | 2.862                    |
| <input type="checkbox"/>            | 26   | <a href="#">GLIA</a>  | 0894-1491 | 11659                 | 6.031         | 5.511                | 1.980           | 147      | 7.4             | 0.02283                           | 1.782                    |
| <input type="checkbox"/>            | 27   | <a href="#">HUM BRAIN MAPP</a>                                      | 1065-9471 | 16505                 | 5.969         | 6.687                | 1.176           | 454      | 6.0             | 0.04232                           | 2.288                    |
| <input type="checkbox"/>            | 28   | <a href="#">BRAIN BEHAV IMMUN</a>                                   | 0889-1591 | 8218                  | 5.889         | 5.895                | 1.278           | 205      | 4.7             | 0.02239                           | 1.728                    |
| <input type="checkbox"/>            | 29   | <a href="#">J PSYCHIATR NEUROSCI</a>                                | 1180-4882 | 2491                  | 5.861         | 6.789                | 0.902           | 41       | 6.0             | 0.00622                           | 2.175                    |
| <input type="checkbox"/>            | 30   | <a href="#">BRAIN STRUCT FUNCT</a>                                  | 1863-2653 | 2478                  | 5.618         | 6.935                | 1.354           | 147      | 3.8             | 0.01071                           | 2.435                    |
| <input type="checkbox"/>            | 31   | <a href="#">MOL AUTISM</a>  | 2040-2392 | 577                   | 5.413         | 5.821                | 0.442           | 52       | 2.4             | 0.00308                           | 2.045                    |
| <input type="checkbox"/>            | 32   | <a href="#">J NEUROINFLAMM</a>                                      | 1742-2094 | 5318                  | 5.408         | 5.632                | 0.605           | 215      | 3.2             | 0.01820                           | 1.524                    |
| <input checked="" type="checkbox"/> | 33   | <a href="#">J CEREBR BLOOD F MET</a>                                | 0271-678X | 15903                 | 5.407         | 5.455                | 0.974           | 232      | 8.0             | 0.02926                           | 1.785                    |
| <input type="checkbox"/>            | 34   | <a href="#">CURR OPIN NEUROL</a>                                    | 1350-7540 | 4789                  | 5.307         | 5.004                | 0.828           | 87       | 6.0             | 0.01265                           | 1.732                    |
| <input type="checkbox"/>            | 35   | <a href="#">PAIN</a>  | 0304-3959 | 31705                 | 5.213         | 6.241                | 1.239           | 284      | 9.6             | 0.05060                           | 2.160                    |
| <input type="checkbox"/>            | 36   | <a href="#">MOL NEUROBIOL</a>                                       | 0893-7648 | 4012                  | 5.137         | 5.460                | 1.209           | 206      | 4.0             | 0.01026                           | 1.509                    |
| <input type="checkbox"/>            | 37   | <a href="#">CORTEX</a>  | 0010-9452 | 6768                  | 5.128         | 5.014                | 0.966           | 178      | 5.8             | 0.01690                           | 1.623                    |
| <input type="checkbox"/>            | 38   | <a href="#">NEUROPHARMACOLOGY</a>                                   | 0028-3908 | 16524                 | 5.106         | 4.823                | 1.182           | 417      | 6.0             | 0.03722                           | 1.454                    |
| <input type="checkbox"/>            | 39   | <a href="#">NEUROBIOL DIS</a>                                       | 0969-9961 | 12714                 | 5.078         | 5.298                | 1.142           | 275      | 5.4             | 0.03304                           | 1.662                    |
| <input type="checkbox"/>            | 40   | <a href="#">NEUROTHERAPEUTICS</a>                                   | 1933-7213 | 2584                  | 5.054         | 5.821                | 1.319           | 72       | 4.5             | 0.00909                           | 1.829                    |

[MARK ALL](#) [UPDATE MARKED LIST](#)

Journals 21 - 40 (of 252)



Page 2 of 13

[Acceptable Use Policy](#)

Copyright © 2016 Thomson Reuters.

**A role of the sodium pump in spreading ischemia in rats**

Sebastian Major, Gabor C. Petzold, Clemens Reiffurth, Olaf Windmüller, Marco Foddis, Ute Lindauer, Eun-Jeung Kang, Jens P. Dreier

*Journal of Cerebral Blood Flow & Metabolism*

First published date: March-18-2016

<http://dx.doi.org/10.1177/0271678X16639059>



## Supplemental Methods

### *NaKA assay*

Enzymatic activity of NaKA (EC 3.6.1.37) was determined using a spectrophotometric enzyme assay (pyruvate kinase–lactate dehydrogenase), coupling the generation of ADP and oxidation of NADH.<sup>1</sup> The homogenization buffer contained in mmol/L: sucrose 250; EGTA 1.25; Tris 10. The reaction buffer contained in mmol/L: EGTA 1; Tris 125; NaCl 120; KCl 12.5; NaN<sub>3</sub> 5; MgCl<sub>2</sub> 5; ATP-MgCl<sub>2</sub> 5;  $\beta$ -NADH 0.25; phosphoenolpyruvate 2.5. Brain tissue was placed on ice, weighed and homogenized (1/10w/v) in ice-cold homogenization buffer in a cooled Potter Braun S homogenizer. The reaction buffer was preincubated at 37°C for 3min in the temperature-controlled cuvette compartment of a continuously recording spectrophotometer (Shimadzu UV-1202, Shimadzu Scientific Instruments Inc., Columbia, USA). The reaction was started by adding 10u/ml pyruvate kinase (type III), 10u/ml lactic dehydrogenase (type XI) and a sample of the homogenized brain tissue to the reaction buffer. Oxidation of  $\beta$ -NADH in the cuvette was continuously monitored at 340nm using the spectrophotometer connected to a PC (PC-1201 software, Shimadzu Scientific Instruments Inc., Columbia, USA). Activity of all ATPases in the homogenate was calculated from the slope of the linear portion of the tracing, the  $\beta$ -NADH extinction coefficient, the volume of the reaction mix and the protein content in the brain tissue sample (with bovine serum albumin as standard).

To specifically determine total NaKA activity, the NaKA inhibitor ouabain (10mmol/L) was added to the reaction mix in a second cuvette. Activity of the NaKA represented the portion of total ATPase activity suppressible by 10mmol/L ouabain. Neurons and glial cells express distinct isoforms of NaKA (i.e.,  $\alpha_2$  and  $\alpha_3$ ). In rats these isoforms can be distinguished from the  $\alpha_1$  isoform by their higher affinity to ouabain.<sup>2</sup> Therefore, in a third cuvette, we applied ouabain at 10 $\mu$ mol/L to the reaction mix in order to determine the activity of the  $\alpha_2/\alpha_3$  isoforms. NaKA activity attributable to the  $\alpha_2/\alpha_3$  isoforms was calculated by subtracting the portion suppressible by 10 $\mu$ mol/L ouabain from the fraction suppressible by 10mmol/L ouabain (i.e., total NaKA activity).<sup>3</sup>

### ***Hb preparation***

Hb was freshly prepared from citrate blood of Wistar rats as described previously.<sup>4</sup> Blood was centrifuged (3000G, 5min at 4°C) and plasma discarded. Cells were washed twice with three to four volumes of cold 0.9% NaCl. The buffy coat was removed. Red blood cells were lysed by sonication. The resulting suspension was centrifuged (15,000G, 10min at 4°C) and the pellet removed. The Hb-containing supernatant was transferred by gel chromatography (Bio-Gel P-6, Bio Rad, Richmond, VA, USA) to the ACSF. The total concentration of Hb in the ACSF was measured as cyanmetHb using a spectrophotometer (Shimadzu UV-1202, Shimadzu Scientific Instruments Inc., Columbia, USA) at 546nm wavelength.

### *Neocortical brain slice experiments*

Twelve male Wistar rats (150-200g) were decapitated under ether anesthesia. Coronal neocortical slices (400 $\mu$ m) were obtained using a vibratome (WPI, Berlin, Germany) as previously described<sup>5</sup> and perfused with prewarmed carbogenated ACSF containing in mmol/L: NaCl 126.0; KCl 3.0; CaCl<sub>2</sub> 2.0; MgSO<sub>4</sub> 2.0; NaHCO<sub>3</sub> 26.0; NaH<sub>2</sub>PO<sub>4</sub> 1.25; glucose 10.0 at pH 7.40 in an interface-type recording chamber. SD was triggered by microinjection of 3mol/L KCl in layers II/III of rat neocortex using a glass capillary (~6 $\mu$ m tip diameter) connected to a pressure ejection system (Ionophor 3; Science Products, Hofheim, Germany). DC potential amplitude, duration at half-maximal amplitude ( $T_{1/2max}$ ) and  $[K^+]_o$  were recorded by two K<sup>+</sup>-sensitive microelectrodes in layers II/III and digitized with a DASH-8u recorder (Astro-Med, West Warwick, RI, USA). Intrinsic optical signals (IOS) were monitored by transilluminating slices and recorded using a microscope-mounted CCD-camera. The control image in a series, captured before SD, was subtracted from each subsequent image, revealing changes in light transmittance (LT) over time. Regions of interest were selected to quantify and compare LT changes. SD velocity was determined by the propagation of the transient LT decrease.

### ***Isolation and cannulation of the rat middle cerebral artery (MCA)***

Male Wistar rats (n = 10; 250-350 g) were anaesthetised with isoflurane and decapitated. All experiments were approved by the Governmental Animal Care and Use Committee (LAGetSi, T 0032/99). The brain was rapidly removed from the skull and put in cold (4°C) 3-(N-morpholino)propanesulfonic acid (MOPS) buffered saline solution with 1% dialysed bovine serum albumin containing in mmol/L: NaCl 144.0; KCl 3.0; CaCl<sub>2</sub> 2.5; MgSO<sub>4</sub> 1.5; NaH<sub>2</sub>PO<sub>4</sub> 1.21; EDTA 0.02; pyruvate 2.0; MOPS 2.0; glucose 5.0 at pH 7.40. For a detailed description of MCA isolation/cannulation see Lindauer and colleagues.<sup>6</sup> Briefly, approximately 1cm of the MCA was carefully dissected from the brain and cannulated on glass micropipettes. The vessel was continuously perfused with MOPS buffered saline solution at a transmural pressure of 80mmHg with a temperature of 37°C. The extraluminal bath contained MOPS buffered saline solution at a temperature of 37°C without bovine serum albumin and was continuously exchanged at a rate of 20ml/min. The vessel chamber was placed on an inverted microscope equipped with a videocamera. A monitor was used for online analysis of the luminal diameter. After preparation, the artery was allowed to equilibrate for one hour. During the entire experiment, temperature, perfusion inflow pressure, and flow rate were kept constant. All pharmacologically active substances were added to the extraluminal bath.

After development of spontaneous tone (at least 20% reduction of resting diameter compared to diameters measured immediately after pressurising), experiments started with

isolated increase of the extraluminal  $K^+$  concentration ( $[K^+]_e$ ) to 20mmol/L (= hypertonic solution) to test the arterial smooth muscle function. Arteries were excluded if they did not show  $K^+$ -induced vasodilation of at least 30%. Thereafter,  $[K^+]_e$  was again lowered to 3mmol/L. In both groups 25 (n=5) and 26 (n=5), we applied MOPS buffered saline solution with an ion composition matching the extracellular changes as previously measured during SD/SI (= cocktail<sub>SD</sub>) containing in mmol/L: NaCl 60.0; KCl 50.0; CaCl<sub>2</sub> 0.1; MgSO<sub>4</sub> 0.7; NaH<sub>2</sub>PO<sub>4</sub> 1.21; EDTA 0.02; pyruvate 2.0; MOPS 2.0; glucose 5.0; pH 6.90.<sup>7</sup> Then, cocktail<sub>SD</sub> was washed out again. Subsequently, L-NNA (Sigma-Aldrich, Deisenhofen, Germany) at 10 $\mu$ mol/L was washed in and, after equilibration, cocktail<sub>SD</sub> was co-applied with L-NNA. Experiments of group 26 were similar to those of group 25 but L-NNA was co-applied with ouabain at 5  $\mu$ M.

## Supplemental References

1. Petzold GC, Einhaupl KM, Dirnagl U, Dreier JP. Ischemia triggered by spreading neuronal activation is induced by endothelin-1 and hemoglobin in the subarachnoid space. *Ann Neurol* 2003; 54(5): 591-8.
2. Blanco G, Mercer RW. Isozymes of the Na-K-ATPase: heterogeneity in structure, diversity in function. *Am J Physiol* 1998; 275(5 Pt 2): F633-50.
3. Pontiggia L, Winterhalter K, Gloor SM. Inhibition of Na,K-ATPase activity by cGMP is isoform-specific in brain endothelial cells. *FEBS letters* 1998; 436(3): 466-70.
4. Dreier JP, Korner K, Ebert N, Gorner A, Rubin I, Back T *et al.* Nitric oxide scavenging by hemoglobin or nitric oxide synthase inhibition by N-nitro-L-arginine induces cortical spreading ischemia when K<sup>+</sup> is increased in the subarachnoid space. *J Cereb Blood Flow Metab* 1998; 18(9): 978-90.
5. Petzold GC, Windmuller O, Haack S, Major S, Buchheim K, Megow D *et al.* Increased extracellular K<sup>+</sup> concentration reduces the efficacy of N-methyl-D-aspartate receptor antagonists to block spreading depression-like depolarizations and spreading ischemia. *Stroke* 2005; 36(6): 1270-7.
6. Lindauer U, Kunz A, Schuh-Hofer S, Vogt J, Dreier JP, Dirnagl U. Nitric oxide from perivascular nerves modulates cerebral arterial pH reactivity. *Am J Physiol Heart Circ Physiol* 2001; 281(3): H1353-63.
7. Windmuller O, Lindauer U, Foddis M, Einhaupl KM, Dirnagl U, Heinemann U *et al.* Ion changes in spreading ischaemia induce rat middle cerebral artery constriction in the absence of NO. *Brain* 2005; 128(Pt 9): 2042-51.

### Supplemental Figure legend

**Figure 1:** Extraluminal application of ionic cocktail matching previously measured ion changes during SD (cocktail<sub>SD</sub>) led to marked dilation in absence and constriction in presence of NOS inhibition similar to an earlier study.<sup>7</sup> Ouabain merely augmented the vasoconstrictor response to the ionic cocktail under NOS inhibition when the response was analyzed in relation with the dilator response to the cocktail in absence of NOS inhibition, which corrects for the differences in vascular reactivity between individual MCAs (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ ,  $n = 5$  in both groups, Two Way Repeated Measures ANOVA [One Factor Repetition] with Bonferroni post-hoc tests).

## Supplemental Table


**Supplemental Table 1. Thapsigargin did not prohibit SI but significantly shortened the durations of both hypoperfusion and negative DC shift compared to a vehicle control group**

|   | rCBF <sub>pre</sub><br>(%) | rCBF <sub>hypo</sub><br>(%) | rCBF <sub>hypo</sub> dur<br>(s) | CBF <sub>hyper</sub><br>(%) | DC <sub>sa</sub> amp<br>(mV) | DC <sub>sa</sub> dur<br>(s) |
|---|----------------------------|-----------------------------|---------------------------------|-----------------------------|------------------------------|-----------------------------|
| <b>L-NNA (1mmol/L)</b>                                |                            |                             |                                 |                             |                              |                             |
| <b>+ thapsigargin (100nmol/L)</b>                     | 99                         | 46                          | 77*                             | 177                         | -3.3                         | 261*                        |
| <b>+ ouabain (50µmol/L)</b><br><b>(group 23, n=6)</b> | (86, 103)                  | (41, 53)                    | (60, 170)                       | (149, 196)                  | (-2.3, -6.1)                 | (208, 369)                  |
| <b>L-NNA (1mmol/L)</b>                                |                            |                             |                                 |                             |                              |                             |
| <b>+ ouabain (50µmol/L)</b>                           | 100                        | 37                          | 271                             | 197                         | -4.1                         | 810                         |
| <b>(group 24, n=6)</b>                                | (93, 119)                  | (30, 39)                    | (159, 468)                      | (185, 244)                  | (-2.2, -6.7)                 | (482, 824)                  |


rCBF<sub>pre</sub> = rCBF level immediately before SD; rCBF<sub>hypo</sub> = lowest rCBF level during initial hypoperfusion in response to SD; rCBF<sub>hypo</sub> dur = duration of rCBF<sub>hypo</sub>; rCBF<sub>hyper</sub> = highest rCBF level during transient hyperemia following SD; DC<sub>sa</sub> amp = amplitude of subarachnoid DC shift during SD; DC<sub>sa</sub> dur = duration of negative subarachnoid DC shift during SD. The two groups were compared with Mann-Whitney Rank Sum Tests (\* $P < 0.05$ ).



**NOS inhibition converts middle cerebral artery dilation in response to cocktail<sub>SD</sub> into significant constriction**



**In relation to the vasodilator response in absence of NOS inhibition, the vasoconstrictor response to cocktail<sub>SD</sub> in presence of NOS inhibition is augmented by ouabain**



Mein Lebenslauf wird aus datenschutzrechtlichen Gründen in der elektronischen Version meiner Arbeit nicht veröffentlicht.

## Publications:

Dirnagl, U.; Przesdzing, I.; Kurreck, C.; **Major, S.** (2016): "A Laboratory Critical Incident and Error Reporting System for Experimental Biomedicine." *PLoS Biol* 14, 12, e2000705.

<http://dx.doi.org/10.1371/journal.pbio.2000705>.

Drenckhahn, C.; Windler, C.; **Major, S.**; Kang, E. J.; Scheel, M.; Vajkoczy, P.; Hartings, J. A.; Woitzik, J.; Dreier, J. P.; group, C. s. (2016): "Complications in Aneurysmal Subarachnoid Hemorrhage Patients With and Without Subdural Electrode Strip for Electrocorticography." *J Clin Neurophysiol* 33, 3, 250-259. <http://dx.doi.org/10.1097/WNP.0000000000000274>.

Dreier, J. P.; Fabricius, M.; Ayata, C.; Sakowitz, O. W.; William Shuttleworth, C.; Dohmen, C.; Graf, R.; Vajkoczy, P.; Helbok, R.; Suzuki, M.; Schiefecker, A. J.; **Major, S.**; Winkler, M. K.; Kang, E. J.; Milakara, D.; Oliveira-Ferreira, A. I.; Reiffurth, C.; Revankar, G. S.; Sugimoto, K.; Dengler, N. F.; Hecht, N.; Foreman, B.; Feyen, B.; Kondziella, D.; Friberg, C. K.; Piilgaard, H.; Rosenthal, E. S.; Westover, M. B.; Maslarova, A.; Santos, E.; Hertle, D.; Sanchez-Porrás, R.; Jewell, S. L.; Balanca, B.; Platz, J.; Hinzman, J. M.; Luckl, J.; Schoknecht, K.; Scholl, M.; Drenckhahn, C.; Feuerstein, D.; Eriksen, N.; Horst, V.; Bretz, J. S.; Jahnke, P.; Scheel, M.; Bohner, G.; Rostrup, E.; Pakkenberg, B.; Heinemann, U.; Claassen, J.; Carlson, A. P.; Kowoll, C. M.; Lublinsky, S.; Chassidim, Y.; Shelef, I.; Friedman, A.; Brinker, G.; Reiner, M.; Kirov, S. A.; Andrew, R. D.; Farkas, E.; Guresir, E.; Vatter, H.; Chung, L. S.; Brennan, K. C.; Lieutaud, T.; Marinesco, S.; Maas, A. I.; Sahuquillo, J.; Dahlem, M. A.; Richter, F.; Herreras, O.; Boutelle, M. G.; Okonkwo, D. O.; Bullock, M. R.; Witte, O. W.; Martus, P.; van den Maagdenberg, A. M.; Ferrari, M. D.; Dijkhuizen, R. M.; Shutter, L. A.; Andaluz, N.; Schulte, A. P.; MacVicar, B.; Watanabe, T.; Woitzik, J.; Lauritzen, M.; Strong, A. J.; Hartings, J. A. (2016): "Recording, analysis, and interpretation of spreading depolarizations in neurointensive care: Review and recommendations of the COSBID research group." *J Cereb Blood Flow Metab*. <http://dx.doi.org/10.1177/0271678X16654496>.

Hartings, J. A.; Shuttleworth, C. W.; Kirov, S. A.; Ayata, C.; Hinzman, J. M.; Foreman, B.; Andrew, R. D.; Boutelle, M. G.; Brennan, K. C.; Carlson, A. P.; Dahlem, M. A.; Drenckhahn, C.; Dohmen, C.; Fabricius, M.; Farkas, E.; Feuerstein, D.; Graf, R.; Helbok, R.; Lauritzen, M.; **Major, S.**; Oliveira-Ferreira, A. I.; Richter, F.; Rosenthal, E. S.; Sakowitz, O. W.; Sanchez-Porrás, R.; Santos, E.; Scholl, M.; Strong, A. J.; Urbach, A.; Westover, M. B.; Winkler, M. K.; Witte, O. W.; Woitzik, J.; Dreier, J. P. (2016): "The continuum of spreading depolarizations in acute cortical lesion development: Examining Leao's legacy." *J Cereb Blood Flow Metab*. <http://dx.doi.org/10.1177/0271678X16654495>.

Bretz, J. S.; Von Dincklage, F.; Woitzik, J.; Winkler, M. K.; **Major, S.**; Dreier, J. P.; Bohner, G.; Scheel, M. (2016): "The Hijdra scale has significant prognostic value for the functional outcome of Fisher grade 3 patients with subarachnoid hemorrhage." *Clin Neuroradiol*. <http://dx.doi.org/10.1007/s00062-016-0509-0>.

Winkler, M. K.; Dengler, N.; Hecht, N.; Hartings, J. A.; Kang, E. J.; **Major, S.**; Martus, P.; Vajkoczy, P.; Woitzik, J.; Dreier, J. P. (2016): "Oxygen availability and spreading depolarizations provide complementary prognostic information in neuromonitoring of aneurysmal subarachnoid hemorrhage patients." *J Cereb Blood Flow Metab*. <http://dx.doi.org/10.1177/0271678X16641424>.

\* **Major, S.**; Petzold, G. C.; Reiffurth, C.; Windmuller, O.; Foddiss, M.; Lindauer, U.; Kang, E. J.; Dreier, J. P. (2016): "A role of the sodium pump in spreading ischemia in rats." *J Cereb Blood Flow Metab*. <http://dx.doi.org/10.1177/0271678X16639059>.

Woitzik, J.; Hecht, N.; Pinczolics, A.; Sandow, N.; **Major, S.**; Winkler, M. K.; Weber-Carstens, S.; Dohmen, C.; Graf, R.; Strong, A. J.; Dreier, J. P.; Vajkoczy, P.; group, C. s. (2013): "Propagation of cortical spreading depolarization in the human cortex after malignant stroke." *Neurology* 80, 12, 1095-1102. <http://dx.doi.org/10.1212/WNL.0b013e3182886932>.

Kang, E. J.\*; **Major, S.\***; Jorks, D.; Reiffurth, C.; Offenhauser, N.; Friedman, A.; Dreier, J. P. (2013): "Blood-brain barrier opening to large molecules does not imply blood-brain barrier opening to small ions." *Neurobiology of disease* 52, 204-218. <http://dx.doi.org/10.1016/j.nbd.2012.12.007>.

Drenckhahn, C.; Brabetz, C.; **Major, S.**; Wiesenthal, D.; Woitzik, J.; Dreier, J. P.; Group, C. S. (2013): "Criteria for the diagnosis of noninfectious and infectious complications after aneurysmal subarachnoid hemorrhage in DISCHARGE-1." *Acta neurochirurgica. Supplement* 115, 153-159. [http://dx.doi.org/10.1007/978-3-7091-1192-5\\_30](http://dx.doi.org/10.1007/978-3-7091-1192-5_30).

Dreier, J. P.; Victorov, I. V.; Petzold, G. C.; **Major, S.**; Windmuller, O.; Fernandez-Klett, F.; Kandasamy, M.; Dirnagl, U.; Priller, J. (2013a): "Electrochemical Failure of the Brain Cortex Is More Deleterious When it Is Accompanied by Low Perfusion." *Stroke; a journal of cerebral circulation* 44, 2, 490-496. <http://dx.doi.org/10.1161/STROKEAHA.112.660589>.

Dreier, J. P.; Drenckhahn, C.; Woitzik, J.; **Major, S.**; Offenhauser, N.; Weber-Carstens, S.; Wolf, S.; Strong, A. J.; Vajkoczy, P.; Hartings, J. A.; Group, C. S. (2013b): "Spreading ischemia after aneurysmal subarachnoid hemorrhage." *Acta neurochirurgica. Supplement* 115, 125-129. [http://dx.doi.org/10.1007/978-3-7091-1192-5\\_26](http://dx.doi.org/10.1007/978-3-7091-1192-5_26).

Woitzik, J.; Dreier, J. P.; Hecht, N.; Fiss, I.; Sandow, N.; **Major, S.**; Winkler, M.; Dahlem, Y. A.; Manville, J.; Diepers, M.; Muench, E.; Kasuya, H.; Schmiedek, P.; Vajkoczy, P. (2012): "Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage." *J Cereb Blood Flow Metab* 32, 2, 203-212. <http://dx.doi.org/10.1038/jcbfm.2011.169>.

Winkler, M. K.; Chassidim, Y.; Lublinsky, S.; Revankar, G. S.; **Major, S.**; Kang, E. J.; Oliveira-Ferreira, A. I.; Woitzik, J.; Sandow, N.; Scheel, M.; Friedman, A.; Dreier, J. P. (2012): "Impaired neurovascular coupling to ictal epileptic activity and spreading depolarization in a patient with subarachnoid hemorrhage: possible link to blood-brain barrier dysfunction." *Epilepsia* 53 Suppl 6, 22-30. <http://dx.doi.org/10.1111/j.1528-1167.2012.03699.x>.

Drenckhahn, C.; Winkler, M. K.; **Major, S.**; Scheel, M.; Kang, E. J.; Pinczolits, A.; Grozea, C.; Hartings, J. A.; Woitzik, J.; Dreier, J. P. (2012): "Correlates of spreading depolarization in human scalp electroencephalography." *Brain : a journal of neurology* 135, Pt 3, 853-868. <http://dx.doi.org/10.1093/brain/aws010>.

Dreier, J. P.; **Major, S.**; Pannek, H. W.; Woitzik, J.; Scheel, M.; Wiesenthal, D.; Martus, P.; Winkler, M. K.; Hartings, J. A.; Fabricius, M.; Speckmann, E. J.; Gorji, A. (2012): "Spreading convulsions, spreading depolarization and epileptogenesis in human cerebral cortex." *Brain : a journal of neurology* 135, Pt 1, 259-275. <http://dx.doi.org/10.1093/brain/awr303>.

Jorks, D.; Milakara, D.; Alam, M.; Kang, E. J.; **Major, S.**; Friedman, A.; Dreier, J. P. (2011a): "A novel algorithm for the assessment of blood-brain barrier permeability suggests that brain topical application of endothelin-1 does not cause early opening of the barrier in rats." *Cardiovascular psychiatry and neurology* 2011, 169580. <http://dx.doi.org/10.1155/2011/169580>.

Jorks, D.; **Major, S.**; Oliveira-Ferreira, A. I.; Kleeberg, J.; Dreier, J. P. (2011b): "Endothelin-1(1-31) induces spreading depolarization in rats." *Acta neurochirurgica. Supplement* 110, Pt 1, 111-117. [http://dx.doi.org/10.1007/978-3-7091-0353-1\\_20](http://dx.doi.org/10.1007/978-3-7091-0353-1_20).

Oliveira-Ferreira, A. I.; Milakara, D.; Alam, M.; Jorks, D.; **Major, S.**; Hartings, J. A.; Luckl, J.; Martus, P.; Graf, R.; Dohmen, C.; Bohner, G.; Woitzik, J.; Dreier, J. P. (2010): "Experimental and preliminary clinical evidence of an ischemic zone with prolonged negative DC shifts surrounded by a normally perfused tissue belt with persistent electrocorticographic depression." *J Cereb Blood Flow Metab* 30, 8, 1504-1519. <http://dx.doi.org/10.1038/jcbfm.2010.40>.

Hartings, J. A.; Watanabe, T.; Dreier, J. P.; **Major, S.**; Vendelbo, L.; Fabricius, M. (2009): "Recovery of slow potentials in AC-coupled electrocorticography: application to spreading depolarizations in rat and human cerebral cortex." *Journal of neurophysiology* 102, 4, 2563-2575.  
<http://dx.doi.org/10.1152/jn.00345.2009>.

Dreier, J. P.; **Major, S.**; Manning, A.; Woitzik, J.; Drenckhahn, C.; Steinbrink, J.; Tolias, C.; Oliveira-Ferreira, A. I.; Fabricius, M.; Hartings, J. A.; Vajkoczy, P.; Lauritzen, M.; Dirnagl, U.; Bohner, G.; Strong, A. J. (2009): "Cortical spreading ischaemia is a novel process involved in ischaemic damage in patients with aneurysmal subarachnoid haemorrhage." *Brain : a journal of neurology* 132, Pt 7, 1866-1881. <http://dx.doi.org/10.1093/brain/awp102>.

Tomkins, O.; Friedman, O.; Ivens, S.; Reiffurth, C.; **Major, S.**; Dreier, J. P.; Heinemann, U.; Friedman, A. (2007): "Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex." *Neurobiology of disease* 25, 2, 367-377.  
<http://dx.doi.org/10.1016/j.nbd.2006.10.006>.

Dreier, J. P.; Kleeberg, J.; Alam, M.; **Major, S.**; Kohl-Bareis, M.; Petzold, G. C.; Victorov, I.; Dirnagl, U.; Obrenovitch, T. P.; Priller, J. (2007): "Endothelin-1-induced spreading depression in rats is associated with a microarea of selective neuronal necrosis." *Exp Biol Med (Maywood)* 232, 2, 204-213, <http://www.ncbi.nlm.nih.gov/pubmed/17259327>  
<http://ebm.rsmjournals.com/content/232/2/204.full.pdf>.

Schonenberger, E.; **Major, S.**; Dewey, M. (2006): "[Questionnaire study on the acceptance of a student initiative for computer-based medical education]." *Gesundheitswesen* 68, 5, 328-332.  
<http://dx.doi.org/10.1055/s-2006-926719>.

Dreier, J. P.; Woitzik, J.; Fabricius, M.; Bhatia, R.; **Major, S.**; Drenckhahn, C.; Lehmann, T. N.; Sarrafzadeh, A.; Willumsen, L.; Hartings, J. A.; Sakowitz, O. W.; Seemann, J. H.; Thieme, A.; Lauritzen, M.; Strong, A. J. (2006): "Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations." *Brain : a journal of neurology* 129, Pt 12, 3224-3237. <http://dx.doi.org/10.1093/brain/awl297>.

Petzold, G. C.; Windmuller, O.; Haack, S.; **Major, S.**; Buchheim, K.; Megow, D.; Gabriel, S.; Lehmann, T. N.; Drenckhahn, C.; Peters, O.; Meierkord, H.; Heinemann, U.; Dirnagl, U.; Dreier, J. P. (2005): "Increased extracellular K<sup>+</sup> concentration reduces the efficacy of N-methyl-D-aspartate receptor antagonists to block spreading depression-like depolarizations and spreading ischemia." *Stroke; a journal of cerebral circulation* 36, 6, 1270-1277.  
<http://dx.doi.org/10.1161/01.STR.0000166023.51307.e0>.

Kleeberg, J.; Petzold, G. C.; **Major, S.**; Dirnagl, U.; Dreier, J. P. (2004): "ET-1 induces cortical spreading depression via activation of the ETA receptor/phospholipase C pathway in vivo." *American journal of physiology. Heart and circulatory physiology* 286, 4, H1339-1346.  
<http://dx.doi.org/10.1152/ajpheart.00227.2003>.

## Acknowledgements

Many people supported the successful preparation of this thesis. I have to thank sincerely to all of you, even if I cannot mention all here.

- First I would like to thank Prof. Dr. Jens P. Dreier for the opportunity to do my thesis, for all the support, discussions, advices, ideas and so much more.
- I thank all friends and colleagues from the Dreier-AG and the Department of Experimental Neurology, especially Dr. Ana Isabel Oliveira Ferreira, Dr. Natalie Ebert, Jörg Kleeberg, Dr. Olaf Windmüller, Marco Foddis, Prof. Ute Lindauer, Clemens Reiffurth and many more for fruitful discussions and their help.
- I am deeply grateful to my family – Gesa, Rieke, Lotti, Kuba and my parents for all the support and all the time.